Your browser doesn't support javascript.
loading
A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy.
Crossnohere, Norah L; Fischer, Ryan; Vroom, Elizabeth; Furlong, Patricia; Bridges, John F P.
Afiliação
  • Crossnohere NL; Department of Biomedical Informatics, The Ohio State University College of Medicine, Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Norah.crossnohere@osumc.edu.
  • Fischer R; Parent Project Muscular Dystrophy, Washington, DC, USA.
  • Vroom E; Duchenne Parent Project, Amsterdam, The Netherlands.
  • Furlong P; Parent Project Muscular Dystrophy, Washington, DC, USA.
  • Bridges JFP; Department of Biomedical Informatics, The Ohio State University College of Medicine, Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA.
Patient ; 15(5): 577-588, 2022 09.
Article em En | MEDLINE | ID: mdl-35243571
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Caregivers routinely inform medical and regulatory decision making in rare pediatric diseases. While differences in treatment preferences across caregivers and patients have been observed for Duchenne muscular dystrophy, this evidence was limited by small samples of patients and results were confounded by patient age and disease progression. We tested caregiver and patient preference concordance for treating Duchenne.

METHODS:

Preferences and demographic/clinical information from 115 caregivers and 107 patients were collected in an international study (response = 80%) using a previously developed discrete-choice experiment consisting of 12 experimentally controlled choice tasks. Each task presented two profiles that varied across four attributes disease progression, drug failure probability, kidney damage risk, and fracture risk. Caregivers and patients were matched 11 based on patient age. We tested for concordance across each task and by comparing caregivers' and patients' maximum acceptable risk of drug failure, kidney damage, and fracture for a slowing of disease progression.

RESULTS:

The final analysis included 77 caregivers and 77 patients. No differences were observed in nationality (p = 0.969), disease stage (p = 0.180), or demographic/clinical factors (p = 0.093-0.857); however, patients were more optimistic (p = 0.030). Caregivers and patients chose similarly across tasks (p = 0.101-0.993). To slow disease progression by 1 year, caregivers and patients would tolerate a 9% and 11% increase in drug failure probability, respectively (p = 0.267). Alternatively, they would accept a 3% and 4% increase in the risk of kidney damage (p = 0.719) or a 15% and 20% increase in the risk of fracture (p = 0.534).

CONCLUSIONS:

Caregivers and patients had concordant preferences for treating Duchenne. Providers and regulators can trust both caregiver and patient report of preferences to inform medical decision making.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cuidadores / Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cuidadores / Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article